Please login to the form below

Not currently logged in
Email:
Password:

UCART19

This page shows the latest UCART19 news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

Among the highlights, Allogene and partner Servier presented phase 1 data for its ‘off-the-shelf’ CAR-T therapy UCART19 in acute lymphoblastic leukaemia (ALL), making the case for an easier

Latest news

  • Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

    It already has one AlloCAR candidate (UCART19) in phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL), and results from the trial could be revealed as early ... If all goes well for UCART19, it could not only

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    The French biotech has another CAR-T therapy in clinical testing - CD19-targeting UCART19 for acute lymphoblastic leukaemia (ALL) - and this is unaffected by the clinical hold, with trials ongoing in ... UCART19 is partnered with Servier and Pfizer.

  • Servier cleared to start US trials CAR-T therapy Servier cleared to start US trials CAR-T therapy

    The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Early results from the CALM trial have already shown that UCART19 can

  • Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

    Another allogeneic CAR-T therapy - the CD19-targeting UCART19 - is already in trials in the UK being run by partners Servier and Pfizer. ... Cellectis' UCART19 has shown positive effects in two leukaemia patients, although one suffered an episode of graft

  • Baxalta’s rare blood cancer drug Oncaspar approved in Europe Baxalta’s rare blood cancer drug Oncaspar approved in Europe

    It could also eventually see further competition from Pfizer's collaboration with Servier and Cellectis, should UCART19 - which was successfully used to treat an 11-month-old British girl with incurable,

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    At this year’s American Society of Haematology (ASH) meeting, Allogene and partner Servier presented phase 1 data for their UCART19 candidate in ALL which revealed impressive response rates.

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    915. Cellectis / Servier. Licence. Product candidates for solid tumours, UCART19 (allogenic CAR-T) for leukaemia and lymphomas (6 candidates in total).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics